|
Xoma Royalty Corporation (NASDAQ: XOMA) |
|
Xoma Royalty Corporation
XOMA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Xoma Royalty growth rates, revenue grew
by 967.92 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 25
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.43 %
Xoma Royalty realized net income compared to net loss a year ago in first quarter of 2025
• More on XOMA's Growth
|
|
Xoma Royalty realized a net loss in trailing twelve months.
Xoma Royalty realized cash reduction of $ -2.66 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 10.2.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.32.
• More on XOMA's Valuation
|
|
|
|
|
Xoma Royalty realized net loss in trailing twelve months.
Xoma Royalty realized cash outflow of $ -2.66per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 10.2.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.32.
Xoma Royalty Price to Book Ratio is at 5.17 lower than Industry Avg. of 34.08. and higher than S&P 500 Avg. of 0.01
• More on XOMA's Valuation
|
|
XOMA's Profitability Comparisons
|
Xoma Royalty achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 37.26 %.
Xoma Royalty net profit margin of 4.43 % is currently ranking no. 51 in Major Pharmaceutical Preparations industry, ranking no. 144 in Healthcare sector and number 1703 in S&P 500.
Profitability by Segment |
Total |
4.43 % |
|
|
Xoma Royalty achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 37.26 %.
Xoma Royalty net profit margin of 4.43 % is currently ranking no. 51 in Major Pharmaceutical Preparations industry, ranking no. 144 in Healthcare sector and number 1703 in S&P 500.
• More on XOMA's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com